The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS) biorepository.
 
Darren Cowzer
No Relationships to Disclose
 
Henry Walch
No Relationships to Disclose
 
Pranita Atri
No Relationships to Disclose
 
Farheen Shah
No Relationships to Disclose
 
Risha Huq
No Relationships to Disclose
 
Danny Khalil
Consulting or Advisory Role - Abbvie; Akamis Bio; Celldex; PsiOxus Therapeutics
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - Intellectual property interests related to CD40, nanotechnology, and in situ vaccination.
 
Wungki Park
Honoraria - American Physician Institute; Curio Science; IntegrityCE
Consulting or Advisory Role - Astellas Pharma; Cerner Enviza; EXACT Therapeutics; Innovent Biologics; Regeneron
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Break Through Cancer (Inst); Merck (Inst); Miracogen (Inst); NIH (Inst); NIH (Inst); Parker Institute for Cancer Immunotherapy (Inst); Revolution Medicines (Inst); The Society of Memorial Sloan Kettering (Inst)
 
Randy Yeh
No Relationships to Disclose
 
Richard Do
No Relationships to Disclose
 
Olca Basturk
No Relationships to Disclose
 
Jinru Shia
Consulting or Advisory Role - PAIGE.AI
 
Michael Berger
Honoraria - SOPHiA Genetics
Consulting or Advisory Role - AstraZeneca; PAIGE.AI
Research Funding - Boundless Bio
Patents, Royalties, Other Intellectual Property - Provisional patent pending for "Systems and Methods for Detecting Cancer via cfDNA Screening"
 
Eileen O'Reilly
Consulting or Advisory Role - Abbvie (I); AstraZeneca; Autem Medical (I); Berry Genomics (I); BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai (I); Exelixis (I); Genentech/Roche (I); Ipsen; J-Pharma (I); Merck; Merus; Novartis; QED Therapeutics (I); Revolution Medicines; SERVIER (I); Vector Health (I); Yiviva (I)
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Revolution Medicines (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma
 
William Jarnagin
No Relationships to Disclose
 
Nikolaus Schultz
Honoraria - OneOncology
 
Mithat Gonen
Travel, Accommodations, Expenses - Genentech
 
David Solit
Stock and Other Ownership Interests - Corramedical, Inc; Elsie Biotechnologies; Fore Biotherapeutics; Function Oncology; Melinda Therapeutics; Pyramid Biosciences; Scorpion Therapeutics; Vividion Therapeutics
Consulting or Advisory Role - BridgeBio Pharma; Corramedical; Elsie Biotechnologies; Fog Therapeutics; Fore Biotherapeutics; Function Oncology; Meliora Therapeutics; PAIGE.AI (I); Pfizer; Pyramid Biosciences; Rain Therapeutics; Scorpion Therapeutics; Vividion Therapeutics
 
Ghassan Abou-Alfa
Consulting or Advisory Role - Abbvie; AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Eisai; Exelixis; Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Neogene Therapeutics (I); Novartis (I); QED Therapeutics; Roche/Genentech; Servier; Tempus (I); Vector Health; Yiviva
Research Funding - Agenus (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); Parker Institute for Cancer Immunotherapy (Inst); Pertzye (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Yiviva (Inst)
 
Walid Chatila
No Relationships to Disclose
 
James Harding
Consulting or Advisory Role - Adaptimmune; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; Elevar Therapeutics; Exelixis; Hepion Pharmaceuticals; Imvax; Jazz Pharmaceuticals; Lilly; Medivir; Merck; QED Therapeutics; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Codiak Biosciences (Inst); Debiopharm Group (Inst); Genoscience Pharma (Inst); Genoscience Pharma (Inst); Incyte (Inst); Kinnate Biopharma; Lilly (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)